IMARC Group, a leading market research company, has recently releases report titled “Mycoplasma Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033,” The study provides a detailed analysis of the industry, including the global mycoplasma testing market share, size, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the mycoplasma testing market?
The global mycoplasma testing market size reached USD 1,018 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,561.7 Million by 2033, exhibiting a growth rate (CAGR) of 10.8% during 2025-2033.
Factors Affecting the Growth of the Mycoplasma Testing Industry:
Increasing Demand for Biopharmaceuticals:
The biopharmaceutical industry has grown rapidly, boosting the need for mycoplasma testing. As biopharmaceuticals become more common in treatments, strict quality control is crucial. Mycoplasma contamination can harm biologics' safety and effectiveness. Thus, regulators require thorough testing. With more biopharmaceuticals and their increasing complexity, advanced testing methods are essential. Now, manufacturers test products during production to meet standards.As a result, the mycoplasma testing market is set to grow. More companies will seek reliable testing to meet these demands.
Technological Advancements in Testing Methods:
Technological innovation is key in the mycoplasma testing market. It shifts testing from traditional to more efficient, accurate methods. Techniques like PCR and next-generation sequencing are now popular. They allow quick, sensitive detection of mycoplasma. These methods cut testing time and boost result accuracy. As labs adopt these, demand for testing services will rise. Moreover, automation in testing increases efficiency and reduces errors. This appeals to manufacturers who want better quality control. The market will evolve with ongoing technological advancements.
Regulatory Pressures and Compliance:
Regulatory bodies worldwide are tightening mycoplasma testing rules for cell cultures and biological products. This shift increases the demand for thorough testing solutions to meet safety standards. Agencies like the FDA and EMA have set specific mycoplasma testing requirements. This pushes manufacturers to implement strong testing protocols. Consequently, there is a greater focus on validating methods and keeping accurate records to meet these demands. Companies that don't comply face heavy penalties, such as product recalls and damage to their reputation. Therefore, the mycoplasma testing market is growing. Businesses are investing more in solutions that meet regulatory expectations, ensuring their products are safe and effective.
Request for a sample copy of this report: https://www.imarcgroup.com/mycoplasma-testing-market/requestsample
Mycoplasma Testing Market Report Segmentation:
Breakup By Product:
- Instruments
- Kits and Reagents
- Services
Kits and reagents account for the majority of shares as they offer standardized and reliable solutions that simplify the testing process.
Breakup By Technology:
- NAAT (Nucleic Acid Amplification Technique)
- ELISA (Enzyme-linked Immunoassay)
- DNA Staining
- Others
Based on the technology, the market has been categorized into NAAT (Nucleic Acid Amplification Technique), ELISA (Enzyme-linked Immunoassay), DNA staining, and others.
Breakup By Application:
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- Others
Cell line testing represents the majority of shares as they are highly susceptible to mycoplasma contamination.
Breakup By End User:
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical and Biotechnology Companies
- Others
Pharmaceutical and biotechnology companies hold the majority of shares as these companies conduct large-scale production of biologics, where contamination can result in significant financial losses.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America holds the leading position owing to a large market for mycoplasma testing driven by its advanced biotechnology sector, well-established pharmaceutical industry, and the presence of strict regulatory frameworks and major market players.
Mycoplasma Testing Market Trends:
The mycoplasma testing market is changing significantly. This is due to the growing complexity of the biopharmaceutical industry and stricter safety regulations. As the demand for biologics and advanced therapies increases, so does the need for mycoplasma testing. Mycoplasmas are wall-less bacteria that can contaminate cell cultures. This contamination can harm the quality and effectiveness of biopharmaceuticals. Therefore, the market for mycoplasma testing is growing quickly. It is driven by the need for strict contamination control and quality assurance. The mycoplasma testing market is growing due to the rise of biopharmaceuticals. These include monoclonal antibodies, vaccines, and cell therapies. Awareness of mycoplasma contamination risks has also increased. Such contamination can harm product quality and patient safety. Now, the FDA and EMA demand strict mycoplasma testing in cell cultures and biological products. Consequently, biopharmaceutical companies are turning to advanced testing solutions to meet these regulations and ensure product safety.
Top Mycoplasma Testing Market Leaders:
The mycoplasma testing market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.
Some of the key players in the market are:
- ATCC
- Bionique Testing Laboratories Inc. (Asahi Kasei Medical Co. Ltd.)
- Bio-Rad Laboratories Inc.
- Charles River Laboratories International Inc.
- Eurofins Scientific SE
- Invivogen
- Lonza Group
- Merck KGaA
- Roche Holding AG
- Sartorius AG
- Thermo Fisher Scientific Inc.
Ask Analyst Browse the full report with TOC and list of Figures: https://www.imarcgroup.com/request?type=reportid=12997flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
